Abstract

SummaryBackgroundGroup B Streptococcus (GBS) disease is a leading cause of neonatal death, but its long-term effects have not been studied after early childhood. The aim of this study was to assess long-term mortality, neurodevelopmental impairments (NDIs), and economic outcomes after infant invasive GBS (iGBS) disease up to adolescence in Denmark and the Netherlands.MethodsFor this cohort study, children with iGBS disease were identified in Denmark and the Netherlands using national medical and administrative databases and culture results that confirmed their diagnoses. Exposed children were defined as having a history of iGBS disease (sepsis, meningitis, or pneumonia) by the age of 89 days. For each exposed child, ten unexposed children were randomly selected and matched by sex, year and month of birth, and gestational age. Mortality data were analysed with the use of Cox proportional hazards models. NDI data up to adolescence were captured from discharge diagnoses in the National Patient Registry (Denmark) and special educational support records (the Netherlands). Health care use and household income were also compared between the exposed and unexposed cohorts.Findings2258 children—1561 in Denmark (born from Jan 1, 1997 to Dec 31, 2017) and 697 in the Netherlands (born from Jan 1, 2000 to Dec 31, 2017)—were identified to have iGBS disease and followed up for a median of 14 years (IQR 7–18) in Denmark and 9 years (6–11) in the Netherlands. 366 children had meningitis, 1763 had sepsis, and 129 had pneumonia (in Denmark only). These children were matched with 22 462 children with no history of iGBS disease. iGBS meningitis was associated with an increased mortality at age 5 years (adjusted hazard ratio 4·08 [95% CI 1·78–9·35] for Denmark and 6·73 [3·76–12·06] for the Netherlands). Any iGBS disease was associated with an increased risk of NDI at 10 years of age, both in Denmark (risk ratio 1·77 [95% CI 1·44–2·18]) and the Netherlands (2·28 [1·64–3·17]). A history of iGBS disease was associated with more frequent outpatient clinic visits (incidence rate ratio 1·93 [95% CI 1·79–2·09], p<0·0001) and hospital admissions (1·33 [1·27–1·38], p<0·0001) in children 5 years or younger. No differences in household income were observed between the exposed and unexposed cohorts.InterpretationiGBS disease, especially meningitis, was associated with increased mortality and a higher risk of NDIs in later childhood. This previously unquantified burden underlines the case for a maternal GBS vaccine, and the need to track and provide care for affected survivors of iGBS disease.FundingThe Bill & Melinda Gates Foundation.TranslationsFor the Dutch and Danish translations of the abstract see Supplementary Materials section.

Highlights

  • Implications of all the available evidence Our findings show that the burden of invasive GBS (iGBS) disease is unacceptably high, despite intrapartum prophylactic antibiotic strategies and advanced neonatal care in high-income countries

  • Group B Streptococcus (GBS) menin­gitis, sepsis, and pneumonia were defined on the basis of discharge diagnoses with the use of International Classification of Diseases (ICD)-10 codes.[16,17,18]

  • We identified 2258 children with a history of iGBS disease, to whom 22 462 children with no history of iGBS disease were matched

Read more

Summary

Introduction

Group B Streptococcus (GBS), Streptococcus agalactiae, is a leading cause of invasive bacterial disease in neonates and young infants (0–89 days).[1,2] Estimates suggest that the burden affects all regions worldwide, with more than 21·7 million pregnant women affected, 55 000 (uncertainty range [UR] 12 000–104 000) stillbirths, 319 000 (145 000–653 000) infant cases of invasive GBS (iGBS) disease, and 90 000 (36 000–169 000) deaths in infants younger than 3 months annually.[3]Assessing the total burden associated with iGBS disease is crucial to design strategies for service provision and prevention, including evaluation of the potential benefit of maternal GBS vaccines that are currently in develop­ ment.[4,5,6] there are important data gaps, notably regarding the long-term health and economic outcomes of individuals after recovering from iGBS disease. Evidence before this study Invasive group B Streptococcus (iGBS) infection is a leading cause of neonatal mortality and morbidity worldwide, but important knowledge gaps exist regarding the long-term outcomes of patients who survive iGBS disease. A 2017 systematic review and meta-analysis of outcomes after iGBS found only 18 small studies (n=453 patients) assessing neurodevelopmental impairment (NDI), almost exclusively before the age of 2 years and without comparator groups. Group B Streptococcus (GBS) disease is a leading cause of neonatal death, but its long-term effects have not been studied after early childhood. The aim of this study was to assess long-term mortality, neurodevelopmental impairments (NDIs), and economic outcomes after infant invasive GBS (iGBS) disease up to adolescence in Denmark and the Netherlands

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.